New startup ideas · Health and bio · Healthcare and bio
startup idea
Benchflow
Order any preclinical assay from inside your ELN; labs sell spare instrument time.
Benchflow is a marketplace for preclinical research services and instrument capacity.
- Marketplace
- Enterprise
- $1-10B market
- Platform others build on
- Global from day one
3/5
venture judge
3
similar startups, last 2 years (17 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,200 · 6 weeks · 30 prospects
Prove that seed-stage biotechs will prepay posted prices for protein characterization runs brokered entirely by hand, for about $1,200 in 6 weeks.
1Focus group: who and where
The founding scientist or head of biologics at a 5-25 person seed or Series A biotech with no in-house SPR or analytical mass spec and no CRO master agreement, sitting on a protein batch that needs binding kinetics or aggregation data before their next board or partnering meeting.
where to find 30 · LinkedIn Sales Navigator filtered to biotechnology, 1-50 employees, titles Founding Scientist, Head of Biology, VP Research; resident company rosters at LabCentral in Cambridge and BioLabs network sites; r/biotech and r/labrats; the PEGS Boston exhibitor and attendee list. For supply, the ABRF core facility directory.
2Sell first, build later
An SPR binding-kinetics run or SEC-MALS aggregation panel at a posted price, ordered on a one-page form, with a 10-business-day guaranteed turnaround and results delivered by a named date; if the date slips, the service fee is refunded.
the ask · $1,800 per SPR kinetics run, $1,200 per SEC-MALS panel, prepaid, with a 15% take inside the posted price
a real yes · A real yes is a cleared prepaid invoice with a sample shipped. 'We will order once the next batch expresses', unpaid trial runs, and labs saying the model is interesting are not yeses.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Twenty supply-side pricing calls
$100 · 10 days
Call 15 academic core facility directors from the ABRF directory and 5 small contract labs. Ask each to commit one assay (SPR kinetics, SEC-MALS, or DSF) at a fixed posted price and turnaround, with a 15% marketplace margin on top, documented in a one-page listing agreement.
keep going if · 6 of 20 sign the one-page listing with a posted price and a named turnaround
2. Rate card to 20 buyers
$200 · 14 days
Build a one-page PDF rate card: 3 assays, posted price, 10-business-day guaranteed turnaround, late means the service fee refunded. Send it to 20 target scientists via Sales Navigator and email and book 15 calls where the only agenda is scoping a real sample they have now.
keep going if · 8 of 15 calls end with a written quote request for a named sample
3. Five concierge prepaid runs
$900 · 21 days
Take 5 orders on a one-page form, invoice 100% up front, then broker by hand: ship the sample to the listed core facility, chase the run, QC the report, deliver by the promised date. Track true turnaround and margin per run in a spreadsheet.
keep going if · 4 of 5 quoted buyers pay the invoice before shipping a sample, and 4 of 5 runs deliver on time
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$1,500
per prospect, refundable
how · Full prepayment of the first run: a one-page order form signed by the buyer plus a Stripe invoice paid before the sample ships; on the supply side, the signed listing agreement fixes the lab's price for 90 days. set up: Stripe Invoicing ↗
what it reserves · A guaranteed instrument slot in the next available window and the posted price locked for the buyer's next 3 orders
refund · Refunded in full if results miss the guaranteed turnaround date or the run fails the facility's QC.
target · 5 prepaid orders from 15 scoping calls within 30 days
Go: build it if
5 prepaid orders totaling $7,000+ in gross merchandise value, 6+ labs under posted-price listings, and on-time delivery on 4 of 5 runs
Kill: stop if
Fewer than 2 prepaid orders from 15 quote-stage calls, or fewer than 3 of 20 labs willing to hold any posted price, which confirms the bespoke-quoting failure mode on the card
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
82
Idea Score, 0-100 · raw 49.9 x 1.64
Warm
competition: more crowded than 41% of ideas · headwind x0.80
+3.3
government priorities, secondary (26 matching grants)
Trend
66
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)70
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
68
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain75
100x potential
45
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis33
- Moat axis100
- Neighbours still alive12
- Technologist judge25
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were order, preclinical, assay, eln, labs, sell, marketplace, research.
The idea in full
- What
- Benchflow is a marketplace for preclinical research services and instrument capacity. Biotech and pharma R&D teams order protein characterization, formulation, ADME or imaging runs at posted price and turnaround; contract labs, academic core facilities and CROs list the hours their instruments sit idle. Ordering happens through embedded integrations inside electronic lab notebooks, LIMS and procurement systems rather than on a separate site, and Benchflow takes a percentage of each order plus a fee for guaranteed turnaround.
- Why now
- The radar shows a wave of companies industrializing exactly these preclinical steps: 10x Science (yc W26) on next-generation protein characterization, AbInitio Bio (yc X26) as the intelligence layer for drug manufacturing, Harbor (yc X26) as an AI-native CRO, and Scala Biodesign raised $16M Series A on 2026-03-31 for its biodesign platform. With 130 new companies tracked in this cluster in the last two years, the buyer side is a long tail of small teams that cannot negotiate CRO master agreements one by one.
- Wedge: first customer and entry point
- Protein characterization runs for seed-stage biotechs: twenty listed labs, one assay category, priced and turnaround-guaranteed, sold through two ELN vendors' integration directories.
- Path to 100x
- Outsourced preclinical research services addressable through self-serve ordering is a $1-10B flow, and a 12% take across it plus embedded ordering in every ELN supports a $1B+ company on software margins. The moat is the order history: real delivered turnaround, failure rates and price per assay across thousands of runs is data no single lab or ELN vendor has, and it becomes the routing engine other tools call.
- Ceiling
- Large pharma keeps buying under master service agreements and only the small-biotech tail transacts, holding gross merchandise value below what a $1B outcome needs.
- Closest real companies, as the generator saw them
- Harbor is building an AI-native CRO and 10x Science operates its own platform; both are supply that Benchflow lists rather than replaces, and neither gives a buyer cross-lab price and turnaround comparison. AbInitio Bio sits on the manufacturing side, downstream of where Benchflow transacts.
- Main risk
- Labs quote every job bespoke and refuse posted pricing, so the marketplace degrades into a lead-gen form with no take rate defensibility.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
12% take on a $1-10B outsourced preclinical flow is real, but the small-biotech tail alone likely cannot carry GMV to $1B.
Bootstrapper
4/5
Seed-stage biotechs already pay CROs bespoke, and a 12% take on posted protein characterization runs bills within a year on software margins.
Operator
4/5
Seed biotechs already pay CROs for these assays and order inside their existing ELN, so spend and workflow both exist today.
Technologist
2/5
An ordering form embedded in ELN directories; the ELN vendors themselves can ship posted-price lab ordering natively before order history compounds.
Risk
2/5
Distribution is two ELN vendors' integration directories, so the marketplace lives or dies on partners who can reprice or delist it.
trends
2/5
A lab-services marketplace was equally feasible in 2013 (Science Exchange), so healthcare's $590M grant pool adds only the secondary point.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (order, preclinical, assay, eln, labs, sell, marketplace, research): 17 all-time, 3 from the last two years. Same matching as Idea Check.
Real world training envs for healthcare AI models
The world’s fastest-growing online jewelry marketplace.
robots & software for farms
Expert STEM reasoning data for frontier AI labs.
Marketplace for America's most essential assets
A direct to consumer marketplace and influencer network for brands
Super Hyperlocal Marketplace for SMEs in Indonesia
Sporttrade | Customer first, always.
Rapid multi-omics profiling for diagnostic labs.
Operator of a web-based platform intended for restaurant supply management. The company's marketplace offers tools to find vendors and buy or sell fresh ingredients effortlessly through its connective marketplace and order management system, enabling clients to increase their business transaction efficiency, and information transparency and improve profitability.
Capturing real-time scientific process data to improve research and enable collaboration.
Developer of a research intelligence platform designed to accelerate biomedical discoveries. The company's platform uses machine learning and artificial intelligence to translate both closed and open-access data into recommendations for specific experiments regarding antibody extraction, enabling researchers and scientists to run successful experiments in less time without wasting resources.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- I-Corps: Translation Potential of an Autonomous Brain-on-a-Chip Platform for Functional Drug Discoveryawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-14
- Development of a safer, more effective formulation of Polymyxin B for treatment of E. coli Infectionawardhigh relevance
NIH / NIAID · SBIR phase I · $306K · posted 2026-08-10
- In vitro myelination assay modeling the environment of MS lesions for predictive discovery of remyelinating therapiesawardhigh relevance
NIH / NINDS · SBIR phase II · $1M · posted 2026-08-06
NIH / NIGMS · SBIR phase II · $377K · posted 2026-08-01
- VivoSphere as an oncology platform for colorectal cancer modeling and drug screeningawardhigh relevance
NIH / NCI · SBIR phase II · $350K · posted 2026-08-01
- SBIR Phase II: Joule-Heated Sorbent-Enhanced Catalysis for High-Purity Methane Production in Semiconductor and Advanced Carbon Material Manufacturingawardhigh relevance
National Science Foundation · SBIR Phase II · $1M · posted 2026-07-24
- Low-cost and high efficiency DNA-based Reverse Genetics Platforms for manufacturing RNA virus products.awardhigh relevance
NIH / NCHHSTP · SBIR phase I · $279K · posted 2025-09-30
- Testing MALT1 inhibitors as a treatment for the rare pediatric inborn error of immunity CARD11 gain of functionawardhigh relevance
NIH / NIAID · SBIR phase I · $313K · posted 2025-09-22
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Marketplace
- Path to 100x
- Platform others build on
- Market size
- $1-10B market
- Capital intensity
- Capital-light (software margins)
- Speed to revenue
- Revenue within a year
- Technical depth
- Integrations, no-code
- Go-to-market
- Partners and channels
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.